# Durvalumab After Concurrent Chemoradiotherapy (cCRT) for Limited-stage Small-cell Lung Cancer (LS-SCLC)

> **NCT07050472** · — · COMPLETED · sponsor: **Anhui Shi, MD** · enrollment: 45 (actual)

## Conditions studied

- Small-cell Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07050472
- **Lead sponsor:** Anhui Shi, MD
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-08-11
- **Primary completion:** 2025-08-12
- **Final completion:** 2025-08-12
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07050472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07050472, "Durvalumab After Concurrent Chemoradiotherapy (cCRT) for Limited-stage Small-cell Lung Cancer (LS-SCLC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07050472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*